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ABSTRACT
Glioblastoma multiforme (GBM) is the most common primary malignant tumors 
originating in the brain parenchyma. At present, GBM patients have a poor prognosis 
despite the continuous progress in therapeutic technologies including surgery, 
radiotherapy, photodynamic therapy, and chemotherapy. Recent studies revealed 
that miR-101 was remarkably down-regulated in kinds of human cancers and was 
associated with aggressive tumor cell proliferation and stem cell self-renewal. Data 
also showed that miR-101 was down-regulated in primary glioma samples and cell 
lines, but the underlying molecular mechanism of the deregulation of miR-101 in 
glioma remained largely unknown. In this study, we found that miR-101 could inhibit 
the proliferation and invasion of glioma cells both in vitro and in vivo by directly 
targeting SOX9 [sex-determining region Y (SRY)-box9 protein]. Silencing of SOX9 
exerted similar effects with miR-101 overexpression on glioma cells proliferation 
and invasion. Quantitative reverse transcription PCR and Western blotting analysis 
revealed a negative relationship between miR-101 and SOX9 in human glioma 
U251MG and U87MG cells, and the luciferase assay indicated that miR-101 altered 
SOX9 expression by directly targeting on 3’UTR. Taken together, our findings suggest 
that miR-101 regulates glioma proliferation, migration and invasion via directly down-
regulating SOX9 both in vitro and in vivo, and miR-101 may be a potential therapeutic 
target for future glioma treatment.
INTRODUCTION
Glioma is the most frequent and malignant brain 
tumor, which usually originates from neural mesenchymal 
cells and can be classified into astrocytoma, glioblastoma, 
medulloblastoma, ependymoma, and oligodendroglioma 
[1]. Glioma is also divided into four grades according 
to the WHO classification system, each grade includes 
varieties of pathological subtypes [2]. Nowadays, the 
prognosis of traditional treatments such as surgery and 
radiation therapy is poor [3–7], resulting in low cure rate 
and short lifetime. The 5-year survival rate of glioblastoma 
is less than 5%, and the average survival period is only 14 
months [8].
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Glioblastoma is the highest grade of glioma. It shows 
low sensitive to radiation therapy and chemotherapy, with 
poor prognosis and high recurrence rate [9–11]. At present, 
the international standard treatment of Glioblastoma 
is temozolomide (TMZ) synchronous chemotherapy 
after surgical resection, following by cycle specific 
chemotherapy by TMZ [12, 13]. However, because of 
the strong radiotherapy and chemotherapy resistance, 
only 30% patients’ median survival period could reach 
2 years, among whom only 9.8% could reach 5 years 
[14]. Theoretically the microRNA (miRNA) exhibits 
biological function of glioma occurrence inhibition at the 
molecular level and improve the survival rate. Studies 
have also shown that the knockout of miR-21 could inhibit 
glioblastoma (GBM) proliferation and induce glioma cells 
apoptosis [15, 16]. These findings provide a potential new 
strategy for clinical treatment of glioma.
MiRNA is a small endogenous single-stranded 
RNA (19-25nt) [17] without open reading frame. As 
a non-coding nucleotide, it plays a vital role in the 
process of many important life activities and diseases 
[18]. MiRNA regulates the expression of target genes in 
transcription level through partial-complementary with 
its 3’-untranslated region [19]. MiRNA participates in 
individual development, cell proliferation, differentiation 
and apoptosis, and other important life activities. All those 
activities mentioned above have great significance in the 
occurrence and development of glioma [20]. For example, 
miR-21, miR-7, miR-128 and miR-221/22 are involved 
in the progression of gliomas [21, 22]. Several researches 
have shown that miR-101 was remarkly downregulated in 
samples from patients and cell lines of human cancers such 
as lung cancer [28], breast cancer [29], laryngeal squamous 
cell carcinoma [30], embryonal rhabdomyosarcoma 
[31] and glioblastoma [32]. In this study, we performed 
functionally investigation of miR-101 in GBM. Our data 
suggested that miR-101 regulated glioma cells proliferation 
and invasion both in vitro and in vivo by directly targeted 
SOX9. Simultaneously, SOX9 was proved to be essential 
for glioma progression. These findings make miR-101 as a 
new target for glioma therapy and verify the importance of 
SOX9 in glioma tumorigenesis.
RESULTS
Overexpression of miR-101 inhibits glioma cell 
invasion, migration, and proliferation in vitro
In order to test the expression level of miR-101 in 
glioma, we collected 20 clinical specimens, including 10 
grade IV cases, 10 grade III cases, 10 grade II cases, 10 
grade I cases and 4 cases of brain injury brain tissues. Our 
data suggested that miR-101 level in glioma tissue is much 
lower compared to normal brain tissue (Figure 1A),and 
the expression level of miR-101 in U87MG, U251MG, 
A172 and T98 glioma cells are lower than that of HEB 
cells (Figure 1B). To test miR-101 function in glioma 
cell lines, U87MG and U251MG were infected with a 
lentivirus encoding the mature sequence of miR-101. The 
infected cells expressed high level of miR-101 both in 
U87MG and U251MG glioma cells (Figure 1C). Wound-
healing assay was performed to detect the effect of miR-
101 on cell migration, and the miR-101-overexpressing 
cells showed considerably slower migration compared 
with the miR-control cells either in U87MG and U251MG 
glioma cells lines (Figure 1D and 1E). Furthermore, Tran-
swell migration assays illustrated that overexpression of 
miR-101 significantly suppressed glioma cell migration 
and invasion (Figure 1F-1I). The invasion ability of miR-
101-U87MG cells was only approximately one-eighth 
of miR-control-U87MG cells, and the migration ability 
was reduced to two-fifth by miR-101-U87MG compared 
with that of miR-control cells (Figure 1F and 1G). The 
invasion ability of miR-101-U251MG cell was only 
approximately one-ninth of miR-control-U251MG cells, 
and the migration ability was reduced to two-fifth by miR-
101-U251MG compared with that of miR-control cells 
(Figure 1H and 1I). MTT assays were taken to examine 
the effect of miR-101 on cell proliferation. As shown in 
Figure 1J and 1K, the cell proliferation rate was decreased 
in the miR-101 group compared with that of the control 
group at 24 to 96 hours after transfection (*P < 0.05 for 
each) in both U87MG and U251MG glioma cells lines, 
indicating that miR-101 could significantly inhibit the 
glioma proliferation.
Overexpression of miR-101 suppresses the tumor 
growth in vivo
In order to investigate the role of miR-101 in glioma, 
we further tested the effect of miR-101 overexpression on 
tumor growth in vivo. According to the previous study, we 
chose U87MG which was easy to form xenograft tumors 
[24]. The miR-101-U87MG cells and their respective 
control cells were implanted into the left and right flanks 
(3.0×106 cells per flank) of nude mice by subcutaneous 
injection, respectively. At 30 days post-injection, data 
showed that the mean volumes of xenograft tumors of 
miR-101-U87 cells were significantly smaller than that of 
miR-control-U87MG cells (n = 5 animals per group, P = 
2.89×10-3; Figure 2A, 2B and 2C). Immunohistochemical 
staining results showed that the number of Ki67 positive 
cells in miR-101-U87MG tumors was less than that in miR-
control-U87MG tumors (Figure 2D and Supplementary 
Figure 1). Thus, miR-101 overexpression significantly 
inhibited the glioma proliferation both in vitro and in vivo.
MiR-101 directly targets SOX9 in GBM
Bioinformatics methods were adopted to predict 
the potential targets of miR-101 in human GBM. The 
TargetScan Program suggested that the 3’UTR region 
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of the SOX9 gene containing the binding sites of miR-
101 (Figure 3A), and the expression level of SOX9 in 
glioma (II-III) tissue was higher than that of the normal 
brains tissue (Figure 3B and Supplementary Figure 5). 
Furthermore, qRT-PCR analysis showed that SOX9 
was obviously down-regulated in miR-101-U87 tumor 
compared with the miR-NC-U87 tumor in tumor xenograft 
model (Supplementary Figure 3), indicating that SOX9 
might be a potential target gene of miR-101. In order to 
test the regulating manner between miR-101 and SOX9, 
we used qRT-PCR and Western blotting to compare the 
expression level of SOX9 in the two glioma cell lines 
transfected with miR-101 or miR-control as shown in 
Figure 3C. Both mRNA level and protein level of SOX9 
was obviously decreased upon miR-101 overexpression 
(Figure 3E and 3D). Then we constructed a luciferase 
reporter plasmid containing the 3’UTR of SOX9. We 
found that the luciferase activity in the Luc-SOX9-UTR-
transfected cells was prominent decreased compared with 
the luciferase activity in the miR-101 target site mutant 
SOX9 3’UTR and negative control cells (Figure 3C). All 
these results suggested that SOX9 was a direct target of 
miR-101 in glioma. We further used immunofluorescence 
to compare the SOX9 expression between miR-control 
U87MG and miR-101-U87MG cells (Supplementary 
Figure 2). The results showed that overexpression of miR-
101 only reduced the SOX9 expression level but did not 
change the SOX9 expression pattern (Figure 3E).
The tumor suppressing function of SOX9 in vitro 
and in vivo
To acknowledge the targeting relationship between 
SOX9 and miR-101 in GBM, we also studied the SOX9 
function in glioma. SOX9 was silenced in U87MG and 
U251MG by sh-SOX9-1 and sh-SOX9-2. The result 
showed that sh-hSOX9-1 showed a better knockdown 
efficiency (Figure 4A and 4B). MTT assay, wound healing 
assays and trans-well assay were used to test the effect of 
SOX9 on glioma cells. U87MG and U251MG glioma cell 
lines were infected with a lentivirus encoding the mature 
sequence of sh-hSOX9-1. First, MTT assay was used to 
examine the effect of SOX9 on U251 MG and U87MG 
cells proliferation. As shown in Figure 4C and 4D, the cell 
proliferation rate was significantly decreased in the miR-
101 group compared with that of control group at 24 to 
Figure 1: Overexpression of miR-101 inhibits glioma cell invasion, migration, and proliferation in vitro. A. miR-101 
expression levels in normal brain tissue and glioma tumor tissues were detected by qRT-PCR analysis. B. The expression level of miR-
101 in U87MG, U251MG, A172 and T98 glioma cells were detected by qRT-PCR analysis. C. The efficiency of lentivirus in U87MG and 
U251MG glioma cell lines were detected by qRT-PCR analysis. D. and E. Representative images of wound healing assay detecting cell 
migration in miR-101-U87MG, NC-U87MG, miR-101-U251MG and NC-U251MG cells. F. Cell invasion and migration of miR-101-
U87MG and NC-U87MG cells were detected by trans-well assay. G. Quantitative analysis of the cell number of U87MG cell trans-well 
invasion and migration assay. H. Cell invasion and migration of miR-101-U251MG and NC-U251MG cells were detected by trans-well 
assay. I. Quantitative analysis of the cell number of U251MG cell trans-well invasion and migration assay. J. and K. Growth curves of 
miR-101-U251MG and NC-U251MG, miR-101-U87MG and NC-U87MG cell lines.
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Figure 2: Overexpression of miR-101 suppresses the tumor growth in vivo. A. and B. Determination of the tumor growth, tumor 
volume was calculated every five days after injection (n = 5). ***p < 0.001. C. Representative image for tumor growth is shown. Nude mice 
were subcutaneously injected with 3.0×106 cells per flank miR-101 or miR-NC stable transfected U87MG cells. D. Immunohistochemistry 
assay detected the level of Ki67 in overexpression-miR-101 and miR-NC xenograft tumor tissues, 200 ×. Scale bar = 100 μm.
Figure 3: SOX9 is a direct target of miR-101. A. Predicted miR-101 target sequences in 3’UTR of SOX9 and mutant containing 
eight mutated nucleotides in 3’UTR of SOX9 (SOX9-mut). B. Immunohistochemistry assay detected the level of SOX9 in glioma (II-III) 
tissue and the normal brains tissue. C. U87MG and U251MG cells were co-transfected with miR-101 and luciferase reporters containing 
either the predicted miRNA target site in SOX9 3’UTR or its corresponding mutant form, the values obtained from the Has-miR-101 vector 
and PGL3 were set as 100%. D. Western blot analysis for the SOX9 expression in U87MG and U251MG cells. E. qRT-PCR analysis of 
SOX9 expression in U87MG and U251MG cells transfected with miR-101 or negative control.
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96 hours after transfection (*P < 0.05). Subsequently, 
trans-well assay illustrated that the invasion ability and 
migration ability was suppressed prominently by SOX9 
silencing both in U87MG and U251MG cells (Figure 4E-
4H). Wound-healing assay was used to detect the effect 
of SOX9 on cell migration (Figure 4I and 4J), and the 
SOX9-KD-U251MG and SOX9-KD-U87MG exhibited 
slower migration compared to the SOX9-control cells, 
respectively. Furthermore, SOX9 silencing also markedly 
inhibited mice xenograft tumor growth (Supplementary 
Figure 4), indicating that SOX9 was essential for glioma 
cell proliferation both in vitro and in vivo.
DISCUSSION
Glioma is one of the most common primary 
malignant tumors in the brain parenchyma. Malignant 
glioma has poor prognosis despite the continuous 
progress in therapeutic technologies, including surgery, 
radiotherapy, photodynamic therapy, and chemotherapy. 
The high incidence and mortality of glioma prompt us 
to search for new therapeutic strategies. The miRNAs 
are kind of endogenous non - coding RNA, they can 
negatively regulate the target genes expression on post - 
transcriptional level through binding to the 3’UTR of 
their mRNA [33]. The deregulation of miRNAs had been 
found in many human cancers, such as ovarian carcinoma 
[34], lung cancer [35,36], liver cancer [37], colon cancer 
[38, 39] and GBM [40]. MiRNA deregulation has become 
a new characteristic of malignant tumor, so some specific 
miRNAs are potentially novel biomarkers of cancer 
diagnosis and prognosis [41–45].
MiR-101 has been reported to be down-regulated 
in several human cancers. Study indicated that miR-101 
could repress lung cancer invasion and proliferation by 
inhibiting interaction of fibroblasts and cancer cells by 
directly targeting CXCL12 [27]. MiR-101 exercises its 
biological function in multiple cancer types by interating 
with CXCR7 [29], CDK8 [30], EZH2 level [31, 47] and 
CPEB1 [32]. In GBM, research showed that miR-101 
Figure 4: The tumor suppressing function of SOX9 in vitro and in vivo. A. Western blotting analysis for the knockdown 
efficiency of SOX9 expression in U87MG and U251MG glioma cell lines. B. qRT-PCR analysis of SOX9 expression in U87 MG and 
U251MG glioma cell lines transfected with sh-SOX9-1, sh-SOX9-2, or respective negative control. C and D. MTT assays tested growth 
curves after knockdowning SOX9 in sh-SOX9-U251MG and sh-SOX9-U87MG cells. E. Transwell assay detected cell invasion and 
migration of SOX9-NC-U87MG and sh-SOX9-1-U87M cells. F. Quantitative analysis the invasion and migration of SOX9-NC-U87MG 
and sh-SOX9-1-U87M cells from three independent experiments. G. Trans-well assay detected cell invasion and migration in SOX9-NC-
U251MG and sh-SOX9-1-U251MG cells. H. Quantitative analysis the invasion and migration of SOX9-NC-U251MG and sh-SOX9-1-
U251MG cells from three independent experiments. I. and J. The wound healing assay detected cell migration in sh-SOX9-1-U251MG, 
NC-U251MG, sh-SOX9-1-U87MG and NC-U87MG cells, representative images were taken at different time points.
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could act as a tumor suppressor by targeting Kruppel-like 
Factor 6 in glioblastom a stem cells [46]. Furthermore, 
miR-101 could reverse the hypomethylation of the LMO3 
promoter in glioma cells [48]. In a word, miR-101 was 
an important regulator in different cancers including 
malignant glioma.
It is noteworthy that a study illustrated that miR-101 
directly targets SOX9 in human hepatocellular carcinoma 
(HCC), and miR-101 could suppress SOX9-dependent 
tumorigenicity and promotes favorable prognosis of 
HCC [49]. While, SOX9 is a high mobility group box 
transcription factor which plays critical roles during 
embryogenesis, differentiation, tumor initiation, invasion 
and stem cell self-renewal [50, 51]. These studies prompt 
that SOX9 might involves in miR-101 tumor suppressing 
process. Therefore, we investigated the relationship 
between SOX9 and miR-101 in glioma in this study. Our 
data confirmed that miR-101 could inhibit proliferation, 
migration and invasion of human glioblastoma by directly 
targeting SOX9. Results also showed that SOX9 was 
essential for glioma tumorigenesis both in vitro and in 
vivo. SOX9 is reported to be regulated by EGFR [52], 
Notch [53], SHH [54], and in turn regulate Akt [55], Wnt 
[56], BMI1 [57] pathways. So we conclude that miR-
101 and SOX9 regulation axis regulates proliferation, 
migration and invasion of human GBM by regulating Akt, 
Wnt, BMI1 signal pathway (Figure 5). This study suggests 
us that miR-101 and SOX9 are key regulators in human 
glioblastoma and provides new therapeutic targets for 
glioma therapy.
MATERIALS AND METHODS
Cell cultures and human tissue Samples
Human glioma cell lines U251MG and U87MG 
were purchased from the Chinese Academy of Sciences 
Cell Bank in 2012, A172, T98 and HEB Normal glial 
cell lines were purchased from Beijing ChuangLian 
biotechnology company (Beijing, China). The authenticity 
of cancer cell lines was tested by short tandem repeat 
profiling. All cancer cells were maintained in high 
glucose DMEM (Invitrogen, Grand Island, NY, USA) 
supplemented with 10% FBS (GIBCO, USA), 100 units/
mL penicillin (NCPC, Shijiazhuang, China) and 100 μg/
mL streptomycin (NCPC, Shijiazhuang, China), and 
incubated in 5% CO2 at 37°C. Specimens of human glioma 
tissues were collected from 25 patients treated in Tangdu 
Hospital of Fourth Military Medical University, P. R. 
China. The normal brain tissue specimens were taken from 
Figure 5: A working model of miR-101 inhibits glioma cell proliferation, invasion and migration by targeting SOX9.
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5 patients who have encountered with traumatic brain 
injuries. The study was approved by the Research Ethics 
Committee of Tangdu Hospital of Fourth Military Medical 
University, P. R. China. All patients involved in this study 
have signed the informed consent be beforehead, and all 
specimens were handled anonymous processing according 
to ethical and legal standards.
Isolation of total RNA and real-time PCR 
analysis
The expression level of miR-101 in glioma cells, 
glioma tissues and traumatic brain injuries tissues was 
measured by real-time quantitative RT-PCR (qRT-PCR). 
Total RNA was isolated from frozen samples and cells 
using Trizol reagent (Invitrogen, CA, USA) under the 
guidance of manufacturer’s protocol. RNA was treated 
with RNase-free DNase I (Roche, Switzerland). Then, 
BcaBest RNA PCR kit (TaKaRa, Dalian, China) was used 
to synthesize the cDNA according to the manufacturer’s 
protocol. All primers were synthesized by Shanghai 
Sangon Technology co., LTD. Quantitative RT-PCR 
was carried out by the iQ5 Multicolor Real-Time PCR 
Detection System (Bio-Rad) with Real-time PCR Master 
Mix (SYBR Green).
Vector construction and transfection
To construct the miR-101 overexpression vector, 
the primers of miR-101 were synthesized by Shanghai 
Generay Biotech Co., Ltd. Primer sets (5’-3’) used for 
amplifying the miR-101 were as follows, (Forward primer: 
CCTGAATTCATTCTAATTTAATTCAACTGG; Reverse 
primer: TATGGATCCTCAGCACAACATGGCTGCAC), 
containing EcoR I and BamH I respectively. Amplified 
miR-101 was then subcloned into pCDH1vector between 
EcoRI and BamH I sites (Promega, Madison, WI, USA). 
Glioma cells were infected with a lentivirus encoding 
the miR-101 mimic oligonucleotide (200nM), negative 
control (NC) and fluorescent GAPDH positive control 
(GenePharma, Shanghai, China). 10 days after infection, 
the cells were harvested and RNA was extracted for qRT-
PCR analysis after filtered with 5ug/ml purine toxins. We 
also constructed SOX9 knock down stable cell lines. The 
premade lentiviral SOX9 short hairpin RNA (shRNA) 
constructs and a shNC constructs were purchased from 
GenePharma (Shanghai, China). The sequences are sh-
SOX9-1: GCATCCTTCAATTTCTGTATA, sh-SOX9-2: 
CTCCACCTTCACCTACATGAA. The interference 
fragment was subcloned into LV3 vector, lentivirus product 
were also purchased from GenePharma (Shanghai, China). 
The DNA sequence of SOX9 3’-UTR including the miR-101 
binding site was amplified by PCR using wild type SOX9 
primers GAATTCTCAGTGGCCAGGCCAACCTTV-5’ 
and CATATGAAACTGATCACATAACACAA-3’, and 
subsequently cloned into the PGL3-luc vector (Promega, 
USA). The predicted miR-101 target site GUACUGU was 
mutated into GAUGACA by site-directed mutagenesis. 
The SOX9 Wild type primers used were GAATT 
CTCAGTGGCCAGGCCAACCTTV-5’ and CATATG 
AAACTGATCACATAACACAA-3’, mutagenic primers 
used were ATATTTTTAGTATGATGACAGTATGATTC
AT-5’ and ATGAATCATACTGTCATCATACTAAAAAT
AT-3’.
MTT assay
The MTT assays were performed as described 
before [23]. In brief, 1 × 104 cells/well was seeded in 96-
well plates with 200 μL culture medium. After treatments, 
the medium was replaced with 200 μL DMEM/FBS 
containing 0.5 mg/mL MTT and incubated at 37°C for 
4 h. The supernatant was then discarded, and the cells 
were lysed in 200 μL DMSO for 10 min at 37°C. The 
optical density (OD) values were measured at 490 nm 
(SpectraMax 190; Molecular Devices Sunnyvale, CA, 
USA).
Cell invasion and migration assays
Cells (2.5 × 105) were suspended in 250 μL serum-
free DMEM and seeded in the top chambers of 24-well 
transwell plates (Corning Inc., Corning, NY, USA) coated 
with 30 μL Matrigel (BD Biosciences, Franklin Lakes, NJ, 
USA). The bottom chambers of the trans-well plates were 
filled with 600 μL DMEM containing 10% FBS. Cells 
were allowed to migrate for 48 hours (invasion assay) 
at 37°C [24]. After migration, cells in the top chambers 
were removed using a cotton swab, and the cells which 
migrated to the bottom chambers were fixed in 4% 
paraformaldehyde (PFA; Sigma-Aldrich) and stained with 
Hoechst staining. The fixed and stained cells were counted 
in five independent fields under a light microscope. At 
least three chambers were counted for each experiment. 
For the migration assay, a similar protocol was followed 
except for the replacement of the top chamber of the 
tran-swell plate with an uncoated chamber. The culture 
medium in the bottom chamber was replaced with DMEM 
containing 2.5% FBS, and cells were allowed to migrate 
for 8 hours.
Wound healing assays
Cells were seeded in 6-well plates and cultured 
until they reached confluence, then a wound was created 
by manually scraping the cell monolayer with a sterile 
200 μL pipette tip. Cells were washed twice with PBS to 
remove the floating cells, and then incubated in DMEM 
supplemented with 1% FBS. Cell migration was observed 
at three preselected time points (0, 12, and 24 hours). 
Images were acquired with a Nikon DS-5M Camera 
System mounted on a phase-contrast Leitz microscope.
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Immunohistochemistry assay
For immunohistochemistry (IHC), 8 μm sections of 
formalin-fixed and paraffin embedded brain tissues were 
first de-waxed and rehydrated before antigen retrieval. The 
SOX9-antibody (1:100 dilution; Abcam, Cambridge, USA) 
and Ki67-antibody (1:100; Roche, Basel, Switzerland) 
were used for this study. After incubation with the primary 
antibodies, the cells were rinsed and incubated for one 
hour with Biotin-labeled secondary antibodies at room 
temperature (Molecular Probes 1:800). Nuclei were 
stained by Hematoxylin. Stained sections were examined 
under a light microscope and the positive cells in five high 
power fields (1×200) were counted for statistic study.
Western blotting
The total cell lysates were dissolved in high KCl lysis 
buffer (10 mM Tris-HCl, pH 8.0, 140 mM NaCl, 300 mM 
KCl, 0.5% Triton X-100,1 mM EDTA, and 0.5% sodium 
deoxycholate) with complete protease inhibitor cocktail 
(Roche). The protein concentrations were determined by a 
protein assay kit (Bio-Rad, Hercules, CA). The Western blot 
assay has been previously described [25]. SOX9-antibody 
was used as primary antibodies. Immunoreactivity was 
visualized by enhanced chemiluminescence amplification 
according to the manufacturer’s protocol (GE healthcare, 
Buckinghamshire, UK).
Luciferase assay
The Hsa-miR-101 vector (GenePharma Co.) and 
PGL3, PGL3-SOX9 3’-UTR, PGL3-SOX9 3’-UTR-
mut were cotransfected into HEK293T cells. Twenty 
four hours after transfection, cell lysates were harvested. 
The luciferase activity was measured using the Dual-
Luciferase Reporter Assay System (Promega, USA).
Animal experiments
All animal experiments were approved by the 
Research Ethics Committee of Tangdu Hospital of Fourth 
Military Medical University, P. R. China. Athymic/nude 
immunocompromised mice were purchased from Fourth 
Military Medical University (Shanxi, China) and breeding 
colonies were maintained in our animal facility under 
standard conditions. Xenografted transplantation of glioma 
cells into athymic/nude immunocompromised mice was 
performed as previously described [26]. There are miR-
NC group and miR-101 group for the U87MG cell lines. 
After pre-transplant preparation of the recipient mice and 
anesthesia with 10% chloral hydrate, isolated miR-101-
U87MG cells (3.0×106 in 5 mL PBS) and their respective 
control cells were implanted into the left and right flanks 
(cells per flank) of nude mice by subcutaneous injection 
to establish the xenograft model. The weight change of 
each animal was measured daily. Tumor volumes were 
determined by measuring the length (a) and the width (b). 
The tumor volume (V) was calculated according to the 
formula V = ab2/2 [27].
Statistical analysis
Independent samples were analyzed by using 
one-sided unpaired Student’s t tests with SPSS17.0 for 
windows (SPSS Inc., Chicago, IL, USA). All statistical 
results from the quantitative analysis of the in vitro 
experiments are presented as means ± SEM, as specified 
in the figure legends. p values < 0.05 were considered 
statistically significant.
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